Pipeline
Robust Portfolio of New Drug Candidates

LISCure develops novel "Game Changers" aiming the first and best-in-class therapeutics.

R&D Pipeline
  • Indication
  • Product
  • Collaborators
  • Discovery
  • In-Vivo Efficacy
  • IND Enabling
  • Phase 1
  • Phase 2
  • Microbiome Therapeutics
  • LIVER DISEASES
    LIVER DISEASES
    IMMUNOLOGY
    NEUROSCIENCE
    LIVER DISEASES
  • LB-P8
    LB-P8
    LB-P6
    LB-P4
    LB-P7

    NASH & NAFLD

    2022

    Cholestatic Liver Disease

    2023

    Auto-immune Disease

    2023

    Parkinson’s Disease/Alzheimer’s Disease

    2023

    Combination Studies

  • Bacteria-mediated
    Immunotherapy
  • ONCOLOGY
  • LB-P2D
    LB-P1
    LB-P3
    LB-P10
    LB-P11

    Solid Tumors (advanced cancers)

    2022

    Solid Tumors

    Solid Tumors

    Solid Tumors

    Solid Tumors

  • Bacterial EV
  • NEUROSCIENCE
    IMMUNOLOGY
  • LB-P4E
    LB-P6E
Microbiome Therapeutics
IndicationNASH&NAFLD
ProductLB-P8
Collaborators
2022
Phase 1
IndicationCholestatic Liver Disease
ProductLB-P8
Collaborators
2023
Phase 1
IndicationAuto-immune Disease
ProductLB-P6
Collaborators
2023
Phase 1
IndicationParkinson's & Alzheimer's
ProductLB-P4
Collaborators
2023
IND Enabling
IndicationCombination Studies
ProductLB-P7
Collaborators
In-Vivo Efficacy
Bacteria-mediated Immunotherapy
IndicationSolid Tumors
ProductLB-P2D
Collaborators
2022
IND Enabling
IndicationSolid Tumors
ProductLB-P1
Collaborators
IND Enabling
IndicationSolid Tumors
ProductLB-P3
Collaborators
IND Enabling
IndicationSolid Tumors
ProductLB-P10
Collaborators
In-Vivo Efficacy
IndicationSolid Tumors
ProductLB-P11
Collaborators
In-Vivo Efficacy
Bacterial EV
IndicationNEUROSCIENCE
ProductLB-P4E
Collaborators
Discovery
IndicationIMMUNOLOGY
ProductLB-P6E
Collaborators
Discovery
  1. 01. Research Collaboration with Mayo Clinic (LB-P7&P8 NASH)
  2. 02. Research Collaboration with Mayo Clinic (LB-P8 Rare Liver Diseases)
  3. 03. Research Collaboration with The Scripps Research Institute (LB-P2D Immuno-Oncology)